RG7637
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 16, 2022
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=88 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed
Trial completion • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Mental Retardation • Psychiatry
February 04, 2022
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=88 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting
Enrollment closed • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Mental Retardation • Psychiatry
April 28, 2021
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
(clinicaltrials.gov)
- P1; N=80; Recruiting; Sponsor: Hoffmann-La Roche; Trial completion date: Apr 2021 ➔ Jul 2021; Trial primary completion date: Apr 2021 ➔ Jul 2021
Clinical • Trial completion date • Trial primary completion date • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Mental Retardation • Psychiatry
July 17, 2020
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
(clinicaltrials.gov)
- P1; N=80; Recruiting; Sponsor: Hoffmann-La Roche
Clinical • New P1 trial • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Psychiatry
1 to 4
Of
4
Go to page
1